TAGRISSO® (osimertinib) plus savolitinib demonstrated statistically significant and clinically meaningful improvements in progression-free and overall survival in MET-driven EGFR-mutated lung cancer after progression on TAGRISSO
The Phase III SAFFRON trial met its primary and key secondary endpoints, demonstrating that TAGRISSO plus savolitinib significantly improved progression-free and overall survival versus platinum-based chemotherapy in patients with MET-driven, EGFR-mutated NSCLC who progressed on prior TAGRISSO therapy. The combination therapy showed a safety profile consistent with the known profiles of the individual medicines, targeting a common resistance mechanism that affects approximately one-third of patients treated with third-generation EGFR-TKIs.
Key figures
- Drug Name
- TAGRISSO (osimertinib) plus savolitinib
- Phase Of Trial
- Phase III
- Centers
- 230
- Countries
- 29
- Patient count
- 338
- Tagrisso dose
- 80 mg once daily
- Savolitinib dose
- 300 mg twice daily
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.